Amalgamated Bank Decreases Holdings in NeoGenomics, Inc. (NASDAQ:NEO)

Amalgamated Bank cut its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 2.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 38,006 shares of the medical research company’s stock after selling 1,004 shares during the quarter. Amalgamated Bank’s holdings in NeoGenomics were worth $561,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the business. Fernwood Investment Management LLC raised its stake in shares of NeoGenomics by 1.0% during the third quarter. Fernwood Investment Management LLC now owns 89,500 shares of the medical research company’s stock worth $1,320,000 after acquiring an additional 900 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in shares of NeoGenomics by 5.0% in the third quarter. Nisa Investment Advisors LLC now owns 45,104 shares of the medical research company’s stock worth $665,000 after buying an additional 2,166 shares during the period. Blue Trust Inc. increased its stake in shares of NeoGenomics by 42.3% in the third quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock worth $46,000 after buying an additional 987 shares during the period. Creative Planning increased its stake in shares of NeoGenomics by 42.3% in the third quarter. Creative Planning now owns 23,547 shares of the medical research company’s stock worth $347,000 after buying an additional 7,004 shares during the period. Finally, Inspire Investing LLC increased its stake in shares of NeoGenomics by 12.0% in the third quarter. Inspire Investing LLC now owns 28,094 shares of the medical research company’s stock worth $414,000 after buying an additional 3,006 shares during the period. 98.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

NEO has been the topic of several analyst reports. Benchmark reaffirmed a “buy” rating and issued a $18.00 target price on shares of NeoGenomics in a research note on Tuesday, September 24th. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 target price on shares of NeoGenomics in a research note on Wednesday, November 6th. Finally, Stephens reaffirmed an “overweight” rating and issued a $19.00 target price on shares of NeoGenomics in a research note on Tuesday, July 30th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $20.25.

NeoGenomics Stock Down 4.7 %

Shares of NeoGenomics stock opened at $15.04 on Friday. The company has a current ratio of 1.99, a quick ratio of 1.91 and a debt-to-equity ratio of 0.37. The company’s fifty day simple moving average is $14.67 and its two-hundred day simple moving average is $14.81. The company has a market cap of $1.93 billion, a P/E ratio of -24.66 and a beta of 1.19. NeoGenomics, Inc. has a 12-month low of $12.77 and a 12-month high of $21.22.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Tuesday, November 5th. The medical research company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.04. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.11%. The firm had revenue of $167.80 million for the quarter, compared to analysts’ expectations of $167.00 million. During the same quarter in the previous year, the business posted ($0.06) EPS. The company’s quarterly revenue was up 10.5% on a year-over-year basis. Research analysts anticipate that NeoGenomics, Inc. will post -0.17 EPS for the current year.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.